Pharmacotherapy & RCTs
Clinical Trials
A message from the editor of this section, Dr Pablo Avanzas
Dr. Pablo Avanzas
MD, PhD, FESC, Consultant in Interventional Cardiology, Hospital Universitario Central Asturias
The purpose of this section is to report the most important current results concerning clinical trials related to cardiovascular pharmacotherapy in various topics such as lipids, hypertension, arrhythmias, heart failure, coronary heart disease, etc. This section will be continuously brought up-to-date with the latest important research in order to provide an ongoing resource.
I hope this tool will contribute to the requirements and necessities of present clinical practice.
Latest Clinical Trials:
Angiotensin-Neprilysin Inhibition as the First-Line Therapy for HF over ACE inhibitors?
Koji Hasegawa
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
Augusto Gallino
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Edgardo Escobar
Rivaroxaban in Peripheral Artery Disease after Revascularization
Gheorghe-Andrei Dan
Targeted Anti-Cytokine Therapies for Treatment of Atherothrombosis
Pablo Avanzas
Impact of Renin–Angiotensin System Inhibitors on Transcatheter Aortic Valve Replacement: Analysis from PARTNER 2
Pablo Avanzas
Long-Term Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54
Pablo Avanzas
SGLT2 Inhibitors Reduce Blood Pressure and Left Ventricular Mass
Thomas Kahan
Antithrombotic Alone for Chronic Coronary Heart Disease and Nonvalvular Atrial Fibrillation
Gheorghe-Andrei Dan
Polypill as a Strategy for Primary and Secondary Cardiovascular Prevention
Edgardo Escobar